Myelodysplastic Syndromes Clinical Trials in New Haven, Connecticut

3 studies are recruiting for myelodysplastic syndromes in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

    The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also chec…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut
    Locations
    177 in total
    Run by
    Takeda

    See if you can join NCT06499285 on ClinicalTrials.gov

  2. A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

    The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    GSK Investigational Site, New Haven, Connecticut
    Locations
    39 in total
    Run by
    GlaxoSmithKline

    See if you can join NCT06847867 on ClinicalTrials.gov

  3. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

    Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Yale University, New Haven, Connecticut
    Locations
    71 in total
    Run by
    Taiho Oncology, Inc.

    See if you can join NCT04256317 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.